Crown Bioscience has held an extraordinary general meeting and announced results of stockholder elections for the company’s 2017 Board of Directors. Dr. Guoliang Yu was re-elected as Chairman of the Board.
The elected Board of Directors comprise global experts and industry leaders from venture capital, corporate management, biotechnology and corporate governance. The complete list of elected directors is as follows:
- Dr. Guoliang Yu, Director, Chairman of Board, re-elected
- Mr. Sandy Chau, Director, re-elected
- Mr. Chen-Chi Kai, Director, re-elected
- Dr. Hongbo Lu, Director, re-elected
- Dr. Jo Shen, Independent Director, re-elected
- Dr. George Lee, Independent Director, re-elected
- Mr. Wu-Fu Chen, Director, newly-elected
- Mr. Andrew Lin, Independent Director, newly-elected
- Dr. Jean-Pierre Wery, Director, newly-elected
The newly elected Director Wu-Fu Chen received his Master of Electrical Engineering degree from University of Florida and later completed his Ph.D. in Computer Science at University of California, Berkeley.
The newly elected Director Andrew Lin received his MBA degree from the University of Chicago and later completed a Master of Electrical and Computer Engineering degree at Massachusetts Institution of Technology.
The newly elected Director Dr. Jean-Pierre Wery, is CEO of Crown Bioscience. Wery has been working for the company since 2008 and was appointed as CEO in 2016. He received his Ph.D. in Physics at Université de Liège and completed his postdoctoral studies at Purdue University.
The elected Board will serve a three year term. The three Independent Directors Jo Shen, George Lee, and Chun Lin will serve as the members of Audit and Compensation Committees. The shareholder voting participating rate is close to 70% and the major shareholders include OrbiMed Healthcare Fund Management, Lilly Asia Ventures, and Center Laboratories.